Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

726
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
726
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

600
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
600
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.8K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unleash the synergies: children's rights and the new strategy for child and adolescent health in Europe and Central Asia.

The Lancet. Child & adolescent health·2026
Same author

A cross sectional study on lens induced glaucoma in COVID era.

Bioinformation·2026
Same author

Epidemiological profile and risk factors of acute appendicitis in India.

Bioinformation·2026
Same author

An international observational study on transition of care from paediatric to adult services for patients with mucopolysaccharidosis II.

BMC health services research·2026
Same author

Melkersson-Rosenthal Syndrome.

QJM : monthly journal of the Association of Physicians·2026
Same author

Prediction of Hip Development Using Femoral Head Cartilage and Acetabular Cartilage Diameters on MRI Images: Comment on Study by Yakita et al.

Journal of pediatric orthopedics·2026

Related Experiment Video

Updated: Mar 12, 2026

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

734

Six-month therapy for abdominal tuberculosis.

Sophie Jullien1, Siddharth Jain, Hannah Ryan

  • 1Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK.

The Cochrane Database of Systematic Reviews
|November 2, 2016
PubMed
Summary
This summary is machine-generated.

Six-month treatment for abdominal tuberculosis (TB) appears adequate, with no significant difference in relapse or cure rates compared to longer regimens. However, more research is needed due to small trial sizes and limited data on specific populations.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K

Related Experiment Videos

Last Updated: Mar 12, 2026

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

734
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K

Area of Science:

  • Infectious Diseases
  • Gastroenterology
  • Clinical Trials

Background:

  • Abdominal tuberculosis (TB) treatment typically follows pulmonary TB guidelines with a six-month regimen.
  • Concerns exist regarding the adequacy of six-month regimens for abdominal TB, especially gastrointestinal TB, due to potential drug malabsorption.
  • Longer treatment durations may increase non-adherence, drug resistance, and costs.

Purpose of the Study:

  • To compare the efficacy and safety of six-month versus longer drug regimens for treating abdominal TB.
  • To evaluate relapse rates and clinical cure following different treatment durations for abdominal TB.

Main Methods:

  • Systematic search of multiple electronic databases and clinical trial registries up to September 2016.
  • Inclusion of randomized controlled trials (RCTs) comparing six-month and longer antituberculous treatment (ATT) regimens for abdominal TB.
  • Primary outcomes included relapse (≥6 months follow-up) and clinical cure; data analyzed using risk ratios (RR) with 95% confidence intervals (CIs).

Main Results:

  • Three RCTs with 328 participants compared six-month and nine-month regimens in adults with intestinal and peritoneal TB.
  • Relapse was uncommon (2/140 vs. 0/129), but the difference was not statistically significant due to small sample size (very low quality evidence).
  • Clinical cure rates were similar between regimens (RR 1.02, 95% CI 0.97 to 1.08; moderate quality evidence); data on death, default, and adverse events were limited.

Conclusions:

  • Current evidence does not suggest six-month regimens are inadequate for intestinal and peritoneal TB, but trial numbers are small.
  • No significant incremental benefits of nine-month regimens were observed for relapse or clinical cure, though confidence in relapse data is very low.
  • Larger studies, including HIV-positive individuals and with longer follow-up, are needed to confirm the safety and efficacy of six-month abdominal TB treatment.